Retevmo (selpercatinib) is a brand-name drug prescribed for certain types of cancer in adults and some children. Retevmo comes as an oral capsule that’s typically taken twice per day, but the dosage ...

FDA simultaneously grants traditional approval in adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, as detected by an FDA-approved test In addition ...

If you have a certain thyroid or lung cancer, your doctor may prescribe Retevmo for you. It’s a prescription drug that’s used to treat the following cancers in specific situations: With advanced ...

INDIANAPOLIS, Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the ...

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring ...

The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer. The Food and Drug Administration (FDA) approved Retevmo ...

Progression-free survival improved with Retevmo as the initial treatment for patients with advanced RET-mutant medullary thyroid cancer. Retevmo (selpercatinib) improved progression-free survival ...

Retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET). This ...

With new tumor shrinkage data, Eli Lilly suggests its Retevmo could be used in a tissue agnostic setting to treat all RET fusion-positive tumors despite their location in the body. (Eli Lilly) () Eli ...

Retevmo (selpercatinib) is a prescription drug used to treat certain types of lung and thyroid cancer. The drug comes as a capsule that you swallow. It’s usually taken twice per day. Retevmo is used ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...